Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis

被引:99
作者
Pilzer, D [1 ]
Fishelson, Z [1 ]
机构
[1] Tel Aviv Univ, Sackler Sch Med, Dept Cell & Dev Biol, IL-69978 Tel Aviv, Israel
基金
以色列科学基金会;
关键词
C9; complement; membrane attack complex; membrane vesiculation; mortalin/GRP75;
D O I
10.1093/intimm/dxh300
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The membrane attack complex (MAC) of the complement system is causing membrane damage and cell death. For protection, cells have adopted several resistance mechanisms, including removal of the membrane-inserted MAC by vesiculation. To identify proteins involved in MAC vesiculation, extracellular proteins released from K562 cells in response to treatment with sub-lytic complement were separated by acrylamide gel electrophoresis and protein bands were extracted, digested into peptides and the peptides were analyzed by mass spectrometry. A 75-kDa protein that was abundant in the supernatant of complement-treated cells was identified as mortalin/GRP75. Analysis by western blotting demonstrated that as early as 5 min after exposure to sub-lytic doses of complement, mortalin was released from K562 cells. Mortalin was released after complete activation of the complement system and formation of C5b-8, and even more so when C5b-9 was formed. Other pore formers, such as streptolysin O and melittin, did not induce release of mortalin. As shown, mortalin can bind to complement C8 and C9 and is shed in vesicles containing C9 and complement MACs. Anti-mortalin antibodies reduced mortalin release from complement-treated cells and elevated the extent of cell death by complement. Inhibitors of protein kinase C and extracellular signal-regulated protein kinase also prevented mortalin release from complement-activated cells. These results suggest that mortalin/GRP75 promotes the shedding of membrane vesicles loaded with complement MAC and protects cells from complement-mediated lysis.
引用
收藏
页码:1239 / 1248
页数:10
相关论文
共 59 条
[21]   Is mortalin a candidate gene for T1DM? [J].
Johannesen, J ;
Pie, A ;
Karlsen, AE ;
Larsen, ZM ;
Jensen, A ;
Vissing, H ;
Kristiansen, OP ;
Pociot, F ;
Nerup, J .
AUTOIMMUNITY, 2004, 37 (6-7) :423-430
[22]   Overexpressed mortalin (mot-2)/mthsp70/GRP75 and hTERT cooperate to extend the in vitro lifespan of human fibroblasts [J].
Kaul, SC ;
Yaguchi, T ;
Taira, K ;
Reddel, RR ;
Wadhwa, R .
EXPERIMENTAL CELL RESEARCH, 2003, 286 (01) :96-101
[23]   Expression of mortalin in patients with chronic atrial fibrillation [J].
Kirmanoglou, K ;
Hannekum, A ;
Schäfler, AE .
BASIC RESEARCH IN CARDIOLOGY, 2004, 99 (06) :404-408
[24]   CYTOLYSIS OF NUCLEATED CELLS BY COMPLEMENT - CELL-DEATH DISPLAYS MULTI-HIT CHARACTERISTICS [J].
KOSKI, CL ;
RAMM, LE ;
HAMMER, CH ;
MAYER, MM ;
SHIN, ML .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (12) :3816-3820
[25]   Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis [J].
Kraus, S ;
Seger, R ;
Fishelson, Z .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2001, 123 (03) :366-374
[26]  
Kraus S, 2000, EUR J IMMUNOL, V30, P1272
[27]   Mitochondrial protein import motor: the ATPase domain of matrix Hsp70 is crucial for binding to Tim44, while the peptide binding domain and the carboxy-terminal segment play a stimulatory role [J].
Krimmer, T ;
Rassow, J ;
Kunau, WH ;
Voos, W ;
Pfanner, N .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (16) :5879-5887
[28]   COMPARISON BETWEEN COMPLEMENT AND MELITTIN HEMOLYSIS - ANTI-MELITTIN ANTIBODIES INHIBIT COMPLEMENT LYSIS [J].
LAINE, RO ;
MORGAN, BP ;
ESSER, AF .
BIOCHEMISTRY, 1988, 27 (14) :5308-5314
[29]   Caveolin-1 and MAL are located on prostasornes secreted by the prostate cancer PC-3 cell line [J].
Llorente, A ;
de Marco, MC ;
Alonso, MA .
JOURNAL OF CELL SCIENCE, 2004, 117 (22) :5343-5351
[30]   Induction of novel Grp75 isoforms by 2-deoxyglucose in human and murine fibroblasts [J].
Merrick, BA ;
Walker, VR ;
He, CY ;
Patterson, RM ;
Selkirk, JK .
CANCER LETTERS, 1997, 119 (02) :185-190